2023
Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).
Meza L, Choi Y, Zhang J, Dizman N, Zengin Z, Ebrahimi H, Barragan-Carrillo R, Hsu J, Chawla N, Chehrazi-Raffle A, Tripathi A, Castro D, Mercier B, Govindarajan A, Chan A, Schork N, Byron S, Pal S. Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 4561-4561. DOI: 10.1200/jco.2023.41.16_suppl.4561.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaClinical benefitLine immunotherapyMicrobial diversityNivolumab/ipilimumabStart of immunotherapyBacterial diversityClear cell histologyPD-L1 expressionRenal cell carcinomaRelative abundanceAvailable RNA sequencing dataRelative microbial abundanceParaffin-embedded samplesRNA sequencing dataRNA-seq readsCell histologyCommon regimenMedian ageLine treatmentCell carcinomaPoor riskShannon diversity indexRCC tumorsImmunotherapyAssociation between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Li X, Agarwal N, Pal S. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 678-678. DOI: 10.1200/jco.2023.41.6_suppl.678.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMedian overall survivalOverall survivalHazard ratioPotential confoundersMedian TTFDisease outcomeMultivariate analysisCox proportional hazards modelEfficacy of ICIsObjective response ratePoor-risk diseaseProgression-free survivalSecond-line treatmentClear cell histologyRenal cell carcinomaProportional hazards modelBaseline characteristicsFree survivalCell histologyMedian ageRisk diseaseTreatment failureEntire cohortCell carcinoma
2022
Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.Peer-Reviewed Original ResearchSystemic therapyNational Comprehensive Cancer Network guidelinesMetastatic renal cell carcinomaStereotactic body radiation therapyMedian total doseClear cell histologyFirst-line therapyFrequent side effectsLines of therapyPreponderance of patientsRetrospective data collectionBody radiation therapyRenal cell carcinomaEfficacy of radiotherapyMRCC patientsMedian doseCell histologyNew regimensSystemic treatmentClinicopathologic characteristicsRT toxicityClinical benefitNetwork guidelinesSame therapyCell carcinomaAssociation of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).
Meza L, Choi Y, Govindarajan A, Dizman N, Zengin Z, Hsu J, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Castro D, Chan A, Zhang G, Byron S, Highlander S, Schork N, Pal S. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 372-372. DOI: 10.1200/jco.2022.40.6_suppl.372.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsClear cell histologyFirst-line treatmentRoutine clinical careRenal cell carcinomaT-testPaucity of dataStudent's t-testParaffin-embedded samplesICI respondersICI therapyCheckpoint inhibitorsCell histologyClinical responseOverall cohortLine treatmentImmunotherapeutic agentsCell carcinomaPoor riskSpecific bacteriaLarge cohortClinical careICI activityPrimary site
2021
First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).
Dizman N, Hsu J, Gillece J, Folkerts M, Reining L, Bergerot P, Meza L, Zengin Z, Muddasani R, Chawla N, Karimi M, Trent J, Highlander S, Pal S. First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO). Journal Of Clinical Oncology 2021, 39: 337-337. DOI: 10.1200/jco.2021.39.6_suppl.337.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaClinical benefitClear cell histologyMajority of ptsRenal cell carcinomaMedian relative abundanceCell histologyMetastatic diseaseClinical outcomesCell carcinomaDiscriminant analysis effect sizePancreatic cancerLinear discriminant analysis effect sizeImmunotherapyLarge seriesSerial samplesPotential associationFungal elementsPatientsMalassezia sppMultiple timepointsMicrobiome compositionTherapyEffect sizeAspergillus fumigatus
2020
Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).
Zengin Z, Dizman N, Salgia N, Jones J, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, Pal S. Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: e17100-e17100. DOI: 10.1200/jco.2020.38.15_suppl.e17100.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRelevant genomic alterationsRenal cell carcinomaGenomic alterationsCell carcinomaPathway alterationsCtDNA next-generation sequencingLines of therapyClear cell histologyMTOR pathway alterationsRate of concordanceCell histologyMedian ageSingle institutionTreatment sequencingClinicopathologic variablesCancer DatabaseCtDNA assessmentInvasive approachUrine specimenBlood specimensCtDNA studiesPatient databasePathogenic alterationsTumor DNA